Replies to post #247031 on Biotech Values

[DewDiligence]

The columns in that NASH-failure table appear to be out of alignment. E.g., Ocaliva is an FXR agonist, and Emricasan is a pan-caspase inhibitor.

Your main point—that so many companies have tried and failed at NASH—is well taken.